Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00384098 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Topically Applied CTA018 in Plaque Psoriasis
A Phase 2 study, sponsored by OPKO Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
NCT00384098 is a Phase 2 study that has completed, run by OPKO Health. The registered enrollment target is 140 participants.
The verdict
NCT00384098, a Phase 2 study, has completed, sponsored by OPKO Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
Study Summary
Vitamin D and its analogs are currently widely used for the treatment of psoriasis. The study drug (CTA018) is a novel analog of vitamin D, and this Phase 2 study will investigate the efficacy and safety of CTA018 in the treatment of psoriasis. Patients with chronic plaque psoriasis will receive one of three doses of CTA018 cream or vehicle (no study drug) daily for 12 weeks.
Interventions
- DRUG CTA018 cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2006-09 |
| Est. Completion | 2007-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00384098
The ClinicalTrials.gov registry entry for NCT00384098 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OPKO Health, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CTA018 cream is the first listed.
NCT00384098 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00384098 about?
NCT00384098 is a clinical study titled "Safety and Efficacy of Topically Applied CTA018 in Plaque Psoriasis". Vitamin D and its analogs are currently widely used for the treatment of psoriasis. The study drug (CTA018) is a novel analog of vitamin D, and this Phase 2 study will investigate the efficacy and safety of CTA018 in the treatment of psoriasis. Patients with chronic plaque psoriasis will receive one...
What is the current status of trial NCT00384098?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2006-09. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00384098?
The interventions under investigation include: CTA018 cream (DRUG).
Who is sponsoring clinical trial NCT00384098?
This trial is sponsored by OPKO Health, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.